Conv. Plasma
Nigella Sativa
Peg.. Lambda

All aspirin studies
Meta analysis
Home COVID-19 treatment researchAspirinAspirin (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 31% Improvement Relative Risk Ventilation 10% Aspirin for COVID-19  Aidouni et al.  ICU PATIENTS Is very late treatment with aspirin beneficial for COVID-19? Prospective study of 1,124 patients in Morocco (Mar 2020 - Mar 2022) Lower mortality with aspirin (p=0.003) Aidouni et al., Research Square, November 2022 Favors aspirin Favors control

The impact of asprin use on the outcome of patients admitted to the intensive care unit with COVID-19 infection

Aidouni et al., Research Square, doi:10.21203/
Nov 2022  
  Source   PDF   All Studies   Meta AnalysisMeta
Prospective study of 1,124 COVID-19 ICU patients, showing lower mortality with aspirin treatment.
risk of death, 30.9% lower, HR 0.69, p = 0.003, treatment 202 of 712 (28.4%), control 165 of 412 (40.0%), NNT 8.6, adjusted per study, multivariable, Cox proportional hazards.
risk of mechanical ventilation, 9.6% lower, RR 0.90, p = 0.33, treatment 189 of 712 (26.5%), control 121 of 412 (29.4%), NNT 35.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Aidouni et al., 30 Nov 2022, prospective, Morocco, preprint, mean age 64.0, 6 authors, study period March 2020 - March 2022.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
The impact of asprin use on the outcome of patients admitted to the intensive care unit with COVID-19 infection
Ghizlane El Aidouni, Amine Bouchlarhem, Houssam Bkiyar, Nabila Ismaili, Noha El Ouafi, Brahim Housni
Background Our objective in this study is to know the impact of the use of asprin in anti-aggregation dose on the evolution during hospitalization of patients admitted in intensive care unit for a severe infection by SARS-COV-2. Methods We conducted a prospective study of patients admitted to our department with severe COVID-19 infection during the period between March 2020 and March 2022, analyzing the difference between the placebo group and the aspirin group on the primary endpoint of all-cause hospital mortality and the composite secondary endpoint of use of mechanical ventilation and thromboembolic events. Results Out of 1124 patients included, 32.6% died, with a protective effect of aspirin against placebo (Hazardratio = 0.691, p = 0.003), for thrombo-embolic complications, 104 events were observed, with a protective effect of aspirin (Hazard-Ratio = 0.448 and p = 0.001), nally regarding mechanical ventilation, there was no remarkable bene t on our sample. Conclusion Given the divergence of results of studies published in the literature, the availability of results of large randomized controlled trials is a necessity.
Abani, Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet, doi:10.1016/S0140-6736(21)01825-0
Ahmed, Rationales and uncertainties for aspirin use in COVID-19: A narrative review, Fam. Med. Community Heal, doi:10.1136/fmch-2020-000741
Ali, Spinler, COVID-19 and thrombosis: From bench to bedside, Trends Cardiovasc. Med, doi:10.1016/j.tcm.2020.12.004
Birnhuber, Between in ammation and thrombosis: endothelial cells in COVID-19, The European respiratory journal, doi:10.1183/13993003.00377-2021
Botton, No association of low-dose aspirin with severe COVID-19 in France: A cohort of 31.1 million people without cardiovascular disease, Res. Pract. Thromb. Haemost, doi:10.1002/rth2.12743
Carbonell, COVID-19 and thromboprophylaxis: Recommendations for our clinical practice in Primary Care, Semergen, doi:10.1016/j.semerg.2020.07.007
Dzeshka, Shantsila, Lip, Effects of Aspirin on Endothelial Function and Hypertension, Curr. Hypertens. Rep, doi:10.1007/s11906-016-0688-8
Formiga, Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from the Spanish SEMI-COVID-19 Registry, Intern. Emerg. Med, doi:10.1007/s11739-021-02870-1
Glatthaar-Saalmüller, Mair, Saalmüller, Antiviral activity of aspirin against RNA viruses of the respiratory tract-an in vitro study, uenza Other Respi. Viruses, doi:10.1111/irv.12421
Gómez-Mesa, Galindo-Coral, Montes, Muñoz Martin, Thrombosis and Coagulopathy in COVID-19, Curr. Probl. Cardiol, doi:10.1016/j.cpcardiol.2020.100742
Ma, Does aspirin have an effect on risk of death in patients with COVID-19? A metaanalysis, Eur. J. Clin. Pharmacol, doi:10.1007/s00228-022-03356-5
Moschonas, Tselepis, SARS-CoV-2 infection and thrombotic complications: a narrative review, J. Thromb. Thrombolysis, doi:10.1007/s11239-020-02374-3
Sahai, Effect of aspirin on short-term outcomes in hospitalized patients with COVID-19, Vasc. Med. (United Kingdom), doi:10.1177/1358863X211012754
Salah, Mehta, Meta-Analysis of the Effect of Aspirin on Mortality in COVID-19, The American journal of cardiology, doi:10.1016/j.amjcard.2020.12.073
Talasaz, Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review, J. Am. Coll. Cardiol, doi:10.1016/j.jacc.2021.02.035
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop